Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr584.00 SEK
Change Today -1.00 / -0.17%
Volume 346.7K
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
As of 11:29 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Open
kr584.50
Previous Close
kr585.00
Day High
kr589.00
Day Low
kr583.00
52 Week High
04/23/15 - kr643.00
52 Week Low
08/15/14 - kr465.60
Market Cap
737.9B
Average Volume 10 Days
450.5K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
--
Dividend
kr2.90
Dividend Yield
4.22%
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZN) Key Developments

Amgen Announces Termination of its Co-Development and Commercialisation Agreement with AstraZeneca

Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The announcement follows Amgen's decision to concentrate on other portfolio priorities after observing suicidal ideation and behaviour events in the brodalumab programme which may result in restrictive labelling. AstraZeneca will confirm its decision on the future development of brodalumab as soon as possible, based on further review of the data.

AstraZeneca to Invest USD 285 Million in New Pharmaceutical Factory in Sweden

AstraZeneca will invest approximately USD 285 million in a new manufacturing facility for its biologics in Sodertalje, Sweden. The facility, which is anticipated to become operational by 2019, is intended for filling and packaging of protein therapeutics, as well as supplying products for AstraZeneca and MedImmune's (the UK firm's biologics research and development unit) clinical studies from the end of 2018. Approximately 150-250 roles are expected to be created at the site by 2019. The expansion of the existing Sodertalje site to include a manufacturing facility for the company's biologics portfolio represents the first phase of a possible three-part programme to increase AstraZeneca's biologics production capabilities.

AstraZeneca Russia and Eurasia Presents at 2015 Russian Pharmaceutical Forum, May-21-2015 10:00 AM

AstraZeneca Russia and Eurasia Presents at 2015 Russian Pharmaceutical Forum, May-21-2015 10:00 AM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Irina Ivanishcheva, Legal Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:SS kr584.00 SEK -1.00

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €86.25 EUR -0.53
Biogen Inc $400.10 USD -2.82
Celgene Corp $114.93 USD -1.09
Eli Lilly & Co $76.41 USD +1.51
Valeant Pharmaceuticals International Inc C$300.48 CAD +2.49
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 67.8x
Price/Sales 3.4x
Price/Book 5.1x
Price/Cash Flow 67.8x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.